Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts

Area of Science:

• Oncology
• Cancer Research
• Pharmacology

Background:

• Malignant peripheral nerve sheath tumors (MPNST) are aggressive and frequently associated with neurofibromatosis type 1 (NF1).
• MPNST exhibits resistance to standard chemotherapy, leading to poor patient outcomes.
• In vitro studies suggested that all-trans retinoic acid (ATRA) and MEK inhibitors (MEKi) could inhibit MPNST proliferation, particularly in combination.

Purpose of the Study:

• To establish a mouse model for investigating the therapeutic efficacy of ATRA and the MEKi PD0325901 on MPNST xenografts.
• To evaluate the response of xenografts derived from NF1-associated MPNST cell lines (S462 and T265) to ATRA and MEKi treatment.

Main Methods:

• Xenotransplantation of human NF1-associated MPNST cell lines (S462, T265) into different strains of immunocompromised mice (Foxn1 nude, Balb/c, SHO, Shorn).
• Immunohistochemical analysis to confirm the characteristic staining pattern of human MPNST xenografts.
• Administration of ATRA and/or MEKi PD0325901 to S462 MPNST xenografts in Foxn1 nude mice, with comparison to placebo treatment.

Main Results:

• Human NF1-associated MPNST derived from S462 cells formed subcutaneous tumors in Foxn1 nude mice, while T265 cells did not form tumors in the tested mouse models.
• Immunohistochemistry confirmed the human origin and characteristic features of the MPNST xenografts.
• Treatment with ATRA and/or MEKi PD0325901 did not demonstrate significant suppression of S462 MPNST xenograft growth compared to placebo in vivo.

Conclusions:

• The established xenograft model using S462 cells in Foxn1 nude mice is suitable for studying MPNST.
• The combination of ATRA and MEKi PD0325901 did not show therapeutic efficacy against established S462 MPNST xenografts in this mouse model.
• Further research is needed to explore alternative therapeutic strategies for NF1-associated MPNST.